EUVIMEDEUVIMED entdecken
ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte Studie

Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose ( NACSTOP 2): A Non‐Inferiority Randomised Controlled Trial

Anselm Wong iD, Richard McNulty, Sarah E Hodgson, Naren Gunja, Andis Graudins

Medical Journal of Australia · 2026

DOI: 10.5694/mja2.70114 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Medical Journal of Australia, 2026. Verfasst von Anselm Wong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Austin Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Acetaminophen, Acetylcysteine, Analgesics, Non-Narcotic, Antidotes. Die Arbeit nennt 28 Literaturangaben. Gefördert von: ACEM Foundation, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To determine whether ceasing acetylcysteine treatment for adults with acute paracetamol overdose after at least 12 h of the two‐bag acetylcysteine regimen is non‐inferior to providing the full 20‐h two‐bag regimen. Study Design Open label, non‐inferiority randomised controlled trial.

Setting

Emergency departments of six Australian metropolitan hospitals (four in Melbourne, two in Sydney), 1 December 2019–31 July 2024.

Participants

Adults who required acetylcysteine treatment following single or staggered paracetamol ingestions whose serum alanine transaminase (ALT) level was below 40 IU/L on presentation, and whose ALT levels were below 40 IU/L and serum paracetamol concentrations below 20 mg/L after 12 h of acetylcysteine treatment.

Intervention

Control group (standard care): two‐bag intravenous acetylcysteine regimen (200 mg/kg over 4 h, followed by 100 mg/kg over 16 h). Intervention group : Acetylcysteine stopped at least 12 h after treatment initiation and the 20‐h infusion period completed with intravenous compound sodium lactate. Main Outcome Measures Difference in ALT level between presentation and 20 h after acetylcysteine treatment initiation; non‐inferiority was defined as the upper limit of the 95% confidence interval (CI) of the difference between median changes in ALT level for the intervention and control groups being less than 3 IU/L.

Results

Of 2830 people who presented with paracetamol overdose, 860 received acetylcysteine treatment; 186 people who met both the presentation and 12‐h acetylcysteine treatment blood test inclusion criteria (median age, 17 years; interquartile range [IQR], 16–23 years; 162 women [87%]) were randomly assigned to the intervention (93 participants) and control groups (93 participants). Median acetylcysteine infusion time in the intervention group was 13 h (IQR, 13–13 h). The median change in ALT level between arrival and 20 h after starting intravenous acetylcysteine treatment was similar for the intervention (−1 IU/L; IQR, −4 to 1 IU/L) and control groups (0 IU/L; IQR, −2 to 2 IU/L); the difference in median change (−1 IU/L; 95% CI, −2 to 1 IU/L) was consistent with the non‐inferiority criterion. No patients developed hepatic injury or hepatotoxicity.

Conclusion

An abbreviated acetylcysteine treatment regimen was non‐inferior to the standard 20‐h two‐bag regimen for people with paracetamol overdose who were at low risk of hepatic failure. Trial Registration ACTRN12619001549112 (prospective)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetaminophenAcetylcysteineAnalgesics, Non-NarcoticAntidotesChemical and Drug Induced Liver InjuryDrug OverdoseAdultFemaleHumansMaleMiddle AgedAlanine TransaminaseAustraliaEmergency Service, Hospital

Stichwörter der Autor:innen

drug overdosepharmaceutical preparationspoisoningtoxicology

Substanzen

AcetaminophenAcetylcysteineAlanine TransaminaseAnalgesics, Non-NarcoticAntidotes

Autor:innen und Institutionen

  • Austin Health, Melbourne, Victoria, Australia.
  • Monash University, Melbourne, Victoria, Australia.
  • Blacktown and Mount Druitt Hospital, Sydney, New South Wales, Australia.
  • The University of Sydney, Sydney, New South Wales, Australia.
  • Western Sydney Toxicology Service, Sydney, New South Wales, Australia.
  • Monash Health, Melbourne, Victoria, Australia.

ORCID-Profile: Anselm Wong

Förderung

  • ACEM Foundation
  • National Health and Medical Research Council

Zitieren

APA

Wong, A., McNulty, R., Hodgson, S. E., Gunja, N., & Graudins, A. (2026). Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose ( NACSTOP 2): A Non‐Inferiority Randomised Controlled Trial. Medical Journal of Australia. https://doi.org/10.5694/mja2.70114

Vancouver

Wong A, McNulty R, Hodgson SE, Gunja N, Graudins A. Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose ( NACSTOP 2): A Non‐Inferiority Randomised Controlled Trial. Medical Journal of Australia. 2026. doi:10.5694/mja2.70114

BibTeX
@article{Wong2026,
  author = {Wong, Anselm and McNulty, Richard and Hodgson, Sarah E and Gunja, Naren and Graudins, Andis},
  title = {Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose ( NACSTOP 2): A Non‐Inferiority Randomised Controlled Trial},
  journal = {Medical Journal of Australia},
  year = {2026},
  doi = {10.5694/mja2.70114}
}
Kostenlos starten →